FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:661-662 March 2, 2000 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Mølbak, K.

To the Editor: Zanamivir (Relenza, Glaxo Wellcome, Research Triangle Park, N.C.), a neuraminidase inhibitor, has been approved by the Food and Drug Administration for the treatment of uncomplicated influenzavirus infection. Zanamivir is marketed as a powder with a lactose vehicle. It is administered orally with the use of an inhalation device (Diskhaler, Glaxo Wellcome). We describe a patient who had respiratory distress that was associated with zanamivir use and required hospitalization.

A 63-year-old man with oxygen-dependent chronic obstructive pulmonary disease was seen by his primary care physician because he believed he was having an exacerbation of his underlying lung disease, . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.